Dermatology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Collect Long-Term Data on Pediatric Cutaneous Mastocytosis

   Rochester, Minn.

   The purpose of this study is to develop a registry to collect long-term data on patients with pediatric cutaneous mastocytosis, and develop better knowledge of the timing, symptoms, resolution or progression of the disease, and predictive markers of its severity.

2. PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

   Jacksonville, Fla.

   The primary purpose of the proof of concept study is to elucidate the efficacy of Secukinumab in the treatment of adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies, and to assess the safety and tolerability over 32 weeks.

3. Development of an Evidence-Based Decision Aid for Acne Treatment

   Rochester, Minn.

   The purpose of this study is to identify the key elements of the clinical discussion between patients and clinicians regarding acne treatment and to develop an evidence-based decision aid for acne treatment. 

4. A Study to Evaluate SX-682 in Subjects with Metastatic Melanoma Concurrently Treated with Pembrolizumab

   Rochester, Minn.

   The primary objective of this study is to determine the safety profile of SX-682 alone and in combination with pembrolizumab in subjects with metastatic melanoma, including the maximum dose that can be administered until adverse effects prevent further dose increases (i.e., the MTD or recommended phase 2 dose), and the dose-limiting toxicity (DLT).

   The secondary objectives are to evaluate the efficacy of SX-682 in combination with pembrolizumab on the basis of the objective response rate, the duration of response, and the rate of progression, and to characterize the single-dose and multidose pharmacokinetic (PK) profile of SX-682.

5. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery

   Rochester, Minn.

   This phase Ib/II trial studies how well dendritic cell therapy after cryosurgery in combination with pembrolizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Cryosurgery, also known as cryoablation or cryotherapy, kills tumor cells by freezing them. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving dendritic cell therapy after cryosurgery in combination with pembrolizumab may work better in treating patients with melanoma.

6. A Study to Evaluate Intravenous Iloprost in Subjects with Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and effectiveness of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.

7. A Study to Evaluate the Effectiveness, Safety and Tolerability of PF-06823859 In Adults With Moderate-to-Severe Dermatomyositis

   Jacksonville, Fla.

   The purpose of this study is to evaluate the investigational drug PF-06823859 and a placebo administered to adult pPatients with moderate-to- severe Dermatomyositis.

8. Evaluating the Effectiveness of Apremilast in the Treatment of Subjects with Canker Sores

   Jacksonville, Fla.

   The purpose of this study is to determine whether Apremalast is an effective treatment for patients with recurring canker sores.

9. A Study to Evaluate The Effectiveness and Safety of Abrocitinib, with or without Topical Medications, in Subjects Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

   Rochester, Minn.

   The purpose of this extension study is to evaluate the effectiveness and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, over approximately two years of study participation. Patients who meet safety step-down criteria will have their dose reduced once, from 200 mg QD to 100 mg QD, or from 100 mg QD to placebo.

10. A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis

    Rochester, Minn.

    The purpose of this study is to assess the safety, effectiveness and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with BRAFV600-mutant melanoma with brain metastasis.